Waltham, MA ; 3/3/20
Amount Funded: $100.5 Million
Type: Series B
Lead Investor: Takeda Ventures
Participating Investor(s): RiverVest Venture Partners, SV Health Ventures, MRL Ventures Fund, V Health Investors, Bay City Capital, Solasta Ventures, M Ventures, Ipsen Ventures (all new investors), F-Prime Capital, Atlas Ventures
Company Description: Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor.
What funding will be used for:
To launch two therapeutic candidates, XTX201 (tumor-selective IL-2) and XTX101 (tumor-selective aCTAL4), advance additional tumor-selective cytokine programs using Xilio’s proprietary technology.
- Joining Xilio’s Board of Directors are Mike Ross and Jayson Punwani (SV Health Investors), Peter Dudek (MRL Ventures Fund) and Nancy Hong (RiverVest Venture Partners).
Data provided by respective company (unless otherwise noted) and researched by StartupsOne for accuracy.